Category Archives: Transhuman News

Cbs News: Scientists Use New Bigfoot DNA To Decode The Bigfoot Genome.
PHOENIX (CBS5) - You #39;ve probably seen this grainy video from 1967, which allegedly shows Bigfoot, but new so-called evidence released Tuesday shows even more...

By: ChannelDeleted

Read more here:
Cbs News: Scientists Use New Bigfoot DNA To Decode The Bigfoot Genome. - Video

Dr. Melba Ketchum on Fox News Channel discussing Sasquatch Genome Project

By: SasquatchDNAVids

See the rest here:
Dr. Melba Ketchum on Fox News Channel discussing Sasquatch Genome Project - Video

Session IV, 150th Symposium: Human Genome
This session discusses topics relevant to the human genome such as Genes, Viruses, and the Future of Medicine as well as Next Generation Genomics. To view th...

By: HSpecialSurgery

Read the original here:
Session IV, 150th Symposium: Human Genome - Video

The Bottom Line

A polished and professional entertainment.

Busan International Film Festival

Kim Sung-su

Nishijima Hidetoshi, Kim Hyo-jin, Hamada Manabu, Maki Yoko, Nakamura Yuri, Ibu Masatoh, Lee Kyeong-young

When the word genome is in a film title expectations for challenging and somehow terrifying science fiction romp are high. Images of evil corporate entities meddling in the very essence of our collective selves or the twisted mutations that will be our future spring to mind. Genome Hazard, based on Tsukasaki Shiros award-winning novel, is neither of those. One part science fiction adventure, one part conspiracy thriller and one part, bafflingly, romance, Genome Hazard cant settle on what it wants to be and so is none of those completely successfully. The Korea/Japan co-production should find moderate success in its home territories where the cast of familiar, if not superstar, faces will attract attention, as will the books built-in audience, and the curiosity factor will carry it a reasonably long way. This kind of sci-fi isnt that common in the region, where traditional monsters, ghosts and robots still carry the day. Any success on the festival circuit will be centered on genre events.

Writer-director Kim Sung-su, for whom Genome Hazard is the second medical science thriller this year after The Flu, is a workmanlike filmmaker that rarely gets fancy and lets his conventional pictures tell the story. That works here, where the height of stylistic innovation is the washed out color of a dying mans last hoursboth physically and mentally contrasted with the saturated brightness of the so-called present. Genome Hazard starts strong: Ishigami Taketo (Nishijima Hidetoshi, Kitano Takeshis Dolls, Cut) is an average salaryman, toiling away as an illustrator at a design firm and freshly married to Miyuki (Maki Yoko) or so he thinks. He gets home one night to find his wife dead but receives a phone call from her while he stares at her corpse. So far so good for classic mess-with-your-head sci-fi. Next thing he knows a gang of thugs claiming to be cops bust in to take him away and the chase to unravel the mystery is on. This is the tip of the proverbial iceberg.

Ishigamis confusion at the circumstances he finds himself in forms the basis of a great thriller, where the hero is the victim of some kind of technological nefariousness he or she cant prove. Its not Philip Dick level paranoid, but its close. The little details compound each other and create a compelling enough mystery with steady forward momentum, aided by a hoary but effective countdown clock. The wheels start to wobble a bit when Ishigami, with the help of Seoul reporter Kang Ji-won (Kim Hyo-jin), discovers hes actually a genius Korean biochemist called Oh Jin-woo whos researching Alzheimers for Japanese biotech giant Sugusawa Research.

To this point Genome Hazard has been shaping up as a pharmacological conspiracy thriller pivoting on an examination of the nature of memory, identity, the connection between the two and the question of what would happen could any be manipulated genetically (answer: bad things). And not even some of the most ridiculous science to grace screens in years can really kill the story. Thats down to a misplaced romance that brings the sci-fi to a screeching halt, and, sadly, Nishijimas histrionics. Kim spend half her screen time looking stunned, but its hard to determine if its because of Ishigamis wild tale or Nishijimas OTT performance. Genome Hazard looks great and frequently visually trumps the characters stupid behavior, but it would be a leaner, more focused film at 90 minutes and without the extra wives.

Production company: Apollon Cinema

Read this article:
Genome Hazard: Busan Review

Oct. 10, 2013 When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.

TCGA ganged up on glioblastoma multiforme (GBM), the most common and lethal of brain tumors, with more than 100 scientists from 14 institutions tracking down the genomic abnormalities that drive GBM.

Five years later, older and wiser, TCGA revisited glioblastoma, producing a broader, deeper picture of the drivers -- and potential therapeutic targets -- of the disease published in the Oct. 10 issue of Cell.

"The first paper in 2008 characterized glioblastoma in important new ways and illuminated the path for all TCGA organ studies that have followed," said senior author Lynda Chin, M.D., professor and chair of Genomic Medicine and scientific director of the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center.

"Our new study reflects major improvements in technology applied to many more tumor samples to more completely characterize the landscape of genomic alterations in glioblastoma," said Chin, who was also co-senior author of the first paper while she was on the faculty of Dana-Farber Cancer Institute in Boston.

"Information generated by this unbiased, data-driven analysis presents new opportunities to discover genomics-based biomarkers, understand disease mechanisms and generate new hypotheses to develop better, targeted therapies," Chin said.

About 23,000 new cases of GBM are predicted in the United States during 2013 and more than 14,000 people expected to die of the disease. Most patients die within 15 months of diagnosis.

Well of rich, detailed data will nurture better treatment

New information about genetic mutations, deletions and amplifications; gene expression and epigenetic regulation; structural changes due to chromosomal alterations, proteomic effects and the molecular networks that drive GBM make for a deep, broad dataset that will underpin research and clinical advances for years to come.

"Our main contribution is this tremendous resource for the GBM research community, which is already heavily relying on the earlier TCGA study," said co-lead author Roeland Verhaak, Ph.D., assistant professor of Bioinformatics and Computational Biology at MD Anderson. "Whatever new treatments people come up with for GBM, I'm very confident that their discovery and development will in some way have benefited from this rich and detailed data set," he said.

See the article here:
Cancer genome atlas exposes more secrets of lethal brain tumor

Public release date: 10-Oct-2013 [ | E-mail | Share ]

Contact: Scott Merville smerville@mdanderson.org 713-792-0661 University of Texas M. D. Anderson Cancer Center

HOUSTON When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.

TCGA ganged up on glioblastoma multiforme (GBM), the most common and lethal of brain tumors, with more than 100 scientists from 14 institutions tracking down the genomic abnormalities that drive GBM.

Five years later, older and wiser, TCGA revisited glioblastoma, producing a broader, deeper picture of the drivers and potential therapeutic targets of the disease published in the Oct. 10 issue of Cell.

"The first paper in 2008 characterized glioblastoma in important new ways and illuminated the path for all TCGA organ studies that have followed," said senior author Lynda Chin, M.D., professor and chair of Genomic Medicine and scientific director of the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center.

"Our new study reflects major improvements in technology applied to many more tumor samples to more completely characterize the landscape of genomic alterations in glioblastoma," said Chin, who was also co-senior author of the first paper while she was on the faculty of Dana-Farber Cancer Institute in Boston.

"Information generated by this unbiased, data-driven analysis presents new opportunities to discover genomics-based biomarkers, understand disease mechanisms and generate new hypotheses to develop better, targeted therapies," Chin said.

About 23,000 new cases of GBM are predicted in the United States during 2013 and more than 14,000 people expected to die of the disease. Most patients die within 15 months of diagnosis.

Well of rich, detailed data will nurture better treatment

Link:
The Cancer Genome Atlas exposes more secrets of lethal brain tumor